AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $3.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$3.1M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 1 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Oct 1- Open
- $39.30
- 52-wk high
- $43.49
- High
- $39.56
- 52-wk low
- $25.52
- Low
- $38.72
- Prev close
- $39.29
- Mkt cap
- $2.29B
- P/E
- 13.0x
- Volume
- 622.9K
- Fwd P/E
- 10.1x
- Beta
- 0.93
- P/S
- 2.4x
- P/B
- 2.4x
- Profit margin
- +18.9%
- Op margin
- +34.2%
- ROE
- +20.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about HRMY filings
Are insiders buying or selling Harmony Biosciences Holdings (HRMY) stock?
Net selling: insiders sold $3.1M and bought $0 of HRMY stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $3.1M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Budur, Kumar (Chief Medical Officer), who sold $3.1M. The latest filing was on Sep 18, 2026.
Which members of Congress have traded HRMY recently?
None. No member of Congress disclosed a HRMY trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this HRMY smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (2)
- MI
Millennium
$18.1M
added
- JC
JPMorgan Chase
$14.7M
added
Sells/Trims (1)
- MI
Millennium
$15.1M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in HRMY right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 32.0% above what analysts expected.
Earnings per share
$0.97 expected
Reports Nov 3, 2026, in 33 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $239.5M | $243.8M | $215.4M | $261.3M |
| Cost of what it sold | $59.6M | $68.5M | $44.5M | $63.2M |
| Gross profit | $179.8M | $175.2M | $170.9M | $198.1M |
| What it spent | ||||
| Research and development | $55.0M | $49.9M | $69.4M | $46.6M |
| Sales and admin | $29.8M | $57.6M | $32.5M | $28.1M |
| Other operating costs | $29.5M | $29.2M | $31.7M | $34.1M |
| Total operating expenses | $114.3M | $136.7M | $133.6M | $108.8M |
| What was left | ||||
| Operating profit | $65.5M | $38.6M | $37.3M | $89.3M |
| Interest on debt | $3.6M | $3.5M | $3.2M | $3.1M |
| Profit before tax | $67.5M | $40.8M | $39.7M | $93.3M |
| Tax | $16.6M | $18.3M | $7.2M | $17.8M |
| Net profit | $50.9M | $22.5M | $32.5M | $75.4M |
| EBITDA | $73.5M | $51.7M | $48.9M | $102.3M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace